Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $7,593 | 439 | 92.3% |
| Travel and Lodging | $627.86 | 2 | 7.6% |
| Education | $1.79 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | $1,114 | 84 | $0 (2024) |
| Ironwood Pharmaceuticals, Inc | $1,011 | 8 | $0 (2017) |
| ABBVIE INC. | $763.36 | 82 | $0 (2024) |
| Lilly USA, LLC | $763.22 | 41 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $403.89 | 24 | $0 (2024) |
| Novo Nordisk Inc | $294.73 | 20 | $0 (2021) |
| PFIZER INC. | $288.23 | 12 | $0 (2021) |
| Indivior Inc. | $287.38 | 13 | $0 (2024) |
| Alkermes, Inc. | $282.26 | 4 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $258.16 | 14 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,036 | 58 | ABBVIE INC. ($180.51) |
| 2023 | $1,082 | 63 | Axsome Therapeutics, Inc. ($187.61) |
| 2022 | $1,045 | 61 | ABBVIE INC. ($240.27) |
| 2021 | $988.04 | 70 | AbbVie Inc. ($159.49) |
| 2020 | $997.18 | 69 | Otsuka America Pharmaceutical, Inc. ($276.92) |
| 2019 | $789.52 | 49 | Otsuka America Pharmaceutical, Inc. ($341.54) |
| 2018 | $738.88 | 43 | Otsuka America Pharmaceutical, Inc. ($253.45) |
| 2017 | $1,547 | 29 | Ironwood Pharmaceuticals, Inc ($1,011) |
All Payment Transactions
442 individual payment records from CMS Open Payments — Page 18 of 18
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/16/2017 | Ironwood Pharmaceuticals, Inc | ZURAMPIC (Drug), LINZESS, VIBERZI | Food and Beverage | In-kind items and services | $17.42 | General |
| Category: Rheumatology | ||||||
| 07/26/2017 | PFIZER INC. | LYRICA (Drug), EUCRISA | Food and Beverage | In-kind items and services | $12.57 | General |
| Category: NEUROSCIENCE;PAIN | ||||||
| 06/21/2017 | Novo Nordisk Inc | Victoza (Drug), Tresiba | Food and Beverage | In-kind items and services | $14.32 | General |
| Category: Diabetes | ||||||
| 06/08/2017 | Merck Sharp & Dohme Corporation | JANUVIA (Drug) | Food and Beverage | In-kind items and services | $92.59 | General |
| Category: ENDOCRINOLOGY | ||||||
| 04/10/2017 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $17.09 | General |
| 04/07/2017 | Ironwood Pharmaceuticals, Inc | ZURAMPIC (Drug) | Travel and Lodging | In-kind items and services | $440.90 | General |
| Category: Rheumatology | ||||||
| 04/07/2017 | Ironwood Pharmaceuticals, Inc | ZURAMPIC (Drug) | Food and Beverage | In-kind items and services | $309.32 | General |
| Category: Rheumatology | ||||||
| 04/07/2017 | Ironwood Pharmaceuticals, Inc | ZURAMPIC (Drug) | Travel and Lodging | In-kind items and services | $186.96 | General |
| Category: Rheumatology | ||||||
| 03/28/2017 | Takeda Pharmaceuticals America, Inc. | Uloric (Drug) | Food and Beverage | In-kind items and services | $15.38 | General |
| Category: Gout/Rheumatology | ||||||
| 03/22/2017 | Valeant Pharmaceuticals North America LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $11.35 | General |
| Category: GASTROENTEROLOGY | ||||||
| 03/06/2017 | Amgen Inc. | Prolia (Biological), Repatha | Food and Beverage | In-kind items and services | $12.65 | General |
| Category: Endocrinology | ||||||
| 02/28/2017 | Takeda Pharmaceuticals America, Inc. | Amitiza (Drug) | Food and Beverage | In-kind items and services | $13.67 | General |
| Category: Lower GI | ||||||
| 02/21/2017 | Ironwood Pharmaceuticals, Inc | ZURAMPIC (Drug), LINZESS, VIBERZI | Food and Beverage | In-kind items and services | $14.15 | General |
| Category: Rheumatology | ||||||
| 02/14/2017 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $12.27 | General |
| Category: PSYCHIATRY | ||||||
| 01/31/2017 | Iroko Pharmaceuticals, LLC | VIVLODEX (Drug), TIVORBEX, ZORVOLEX | Food and Beverage | In-kind items and services | $13.93 | General |
| Category: NSAID | ||||||
| 01/30/2017 | Ironwood Pharmaceuticals, Inc | ZURAMPIC (Drug), LINZESS, VIBERZI | Food and Beverage | In-kind items and services | $17.29 | General |
| Category: Rheumatology | ||||||
| 01/12/2017 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $17.38 | General |
| Category: PSYCHIATRY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 5 | 111 | 200 | $5,728 | $1,556 |
| 2020 | 8 | 242 | 474 | $17,632 | $4,273 |
All Medicare Procedures & Services
13 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 12 | 17 | $2,011 | $517.66 | 25.7% |
| 80305 | Testing for presence of drug, read by direct observation | Office | 2021 | 11 | 32 | $901.00 | $403.20 | 44.8% |
| 85610 | Blood test, clotting time | Office | 2021 | 13 | 63 | $568.00 | $266.38 | 46.9% |
| 93000 | Routine ekg using at least 12 leads including interpretation and report | Office | 2021 | 53 | 53 | $2,016 | $247.43 | 12.3% |
| 81002 | Urinalysis, manual test | Office | 2021 | 22 | 35 | $232.00 | $121.80 | 52.5% |
| 17000 | Destruction of skin growth | Office | 2020 | 24 | 30 | $2,250 | $1,358 | 60.4% |
| 93000 | Routine ekg using at least 12 leads including interpretation and report | Office | 2020 | 89 | 92 | $5,152 | $761.38 | 14.8% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 15 | 27 | $2,406 | $575.66 | 23.9% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 14 | 24 | $4,237 | $539.57 | 12.7% |
| 85610 | Blood test, clotting time | Office | 2020 | 17 | 117 | $1,170 | $498.06 | 42.6% |
| 17003 | Destruction of 2-14 skin growths | Office | 2020 | 17 | 66 | $1,650 | $282.01 | 17.1% |
| 81002 | Urinalysis, manual test | Office | 2020 | 46 | 59 | $354.00 | $196.89 | 55.6% |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 2020 | 20 | 59 | $413.00 | $60.94 | 14.8% |
About Dr. Samuel Gillespie, MD
Dr. Samuel Gillespie, MD is a Community Health Worker healthcare provider based in Moulton, Alabama. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/13/2005. The National Provider Identifier (NPI) number assigned to this provider is 1184612095.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Samuel Gillespie, MD has received a total of $8,223 in payments from pharmaceutical and medical device companies, with $1,036 received in 2024. These payments were reported across 442 transactions from 44 companies. The most common payment nature is "Food and Beverage" ($7,593).
As a Medicare-enrolled provider, Gillespie has provided services to 353 Medicare beneficiaries, totaling 674 services with total Medicare billing of $5,829. Data is available for 2 years (2020–2021), covering 13 distinct procedure/service records.
Practice Information
- Specialty Community Health Worker
- Other Specialties Dermatology, Adult Medicine
- Location Moulton, AL
- Active Since 10/13/2005
- Last Updated 03/07/2023
- Taxonomy Code 172V00000X
- Entity Type Individual
- NPI Number 1184612095
Products in Payments
- REXULTI (Drug) $1,150
- ZURAMPIC (Drug) $986.04
- VRAYLAR (Drug) $557.46
- TRULICITY (Drug) $369.12
- Kerendia (Drug) $258.16
- SUBLOCADE (Drug) $256.49
- LYBALVI (Drug) $256.17
- MOUNJARO (Drug) $221.73
- UBRELVY (Drug) $211.18
- Auvelity (Drug) $206.05
- JARDIANCE (Drug) $190.36
- BREZTRI (Drug) $181.47
- FREESTYLE LIBRE 2 (Device) $170.96
- Tresiba (Drug) $161.48
- FARXIGA (Drug) $158.04
- ENTRESTO (Drug) $156.99
- Zubsolv (Drug) $144.20
- Otezla (Drug) $140.71
- Vascepa (Drug) $127.22
- XIFAXAN (Drug) $119.76
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.